Title | Strategy of developing nucleic acid-based universal monkeypox vaccine candidates |
Author | |
Corresponding Author | He,Yunjiao; Wang,Peng George |
Publication Years | 2022-10-27
|
DOI | |
Source Title | |
ISSN | 1664-3224
|
EISSN | 1664-3224
|
Volume | 13 |
Abstract | Until May 2022, zoonotic infectious disease monkeypox (MPX) caused by the monkeypox virus (MPXV) was one of the forgotten viruses considered to be geographically limited in African countries even though few cases outside of Africa were identified. Central and West African countries are known to be endemic for MPXV. However, since the number of human MPX cases has rapidly increased outside of Africa the global interest in this virus has markedly grown. The majority of infected people with MPXV have never been vaccinated against smallpox virus. Noteworthily, the MPXV spreads fast in men who have sex with men (MSM). Preventive measures against MPXV are essential to be taken, indeed, vaccination is the key. Due to the antigenic similarities, the smallpox vaccine is efficient against MPXV. Nevertheless, there is no specific MPXV vaccine until now. Nucleic acid vaccines deserve special attention since the emergency approval of two messenger RNA (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines in 2020. This milestone in vaccinology has opened a new platform for developing more mRNA- or DNA-based vaccines. Certainly, this type of vaccine has a number of advantages including time- and cost-effectiveness over conventional vaccines. The platform of nucleic acid-based vaccines gives humankind a huge opportunity. Ultimately, there is a strong need for developing a universal vaccine against MPXV. This review will shed the light on the strategies for developing nucleic acid vaccines against MPXV in a timely manner. Consequently, developing nucleic acid-based vaccines may alleviate the global threat against MPXV. |
Keywords | |
URL | [Source Record] |
Indexed By | |
Language | English
|
SUSTech Authorship | First
; Corresponding
|
Funding Project | Shenzhen Science and Technology Innovation Program[KQTD20200909113758004];
|
WOS Research Area | Immunology
|
WOS Subject | Immunology
|
WOS Accession No | WOS:000882749000001
|
Publisher | |
Scopus EID | 2-s2.0-85141690091
|
Data Source | Scopus
|
Citation statistics |
Cited Times [WOS]:4
|
Document Type | Journal Article |
Identifier | http://kc.sustech.edu.cn/handle/2SGJ60CL/411825 |
Department | Department of Pharmacology 南方科技大学医学院 |
Affiliation | Department of Pharmacology,School of Medicine,Southern University of Science and Technology,Shenzhen,China |
First Author Affilication | Department of Pharmacology; School of Medicine |
Corresponding Author Affilication | Department of Pharmacology; School of Medicine |
First Author's First Affilication | Department of Pharmacology; School of Medicine |
Recommended Citation GB/T 7714 |
Papukashvili,Dimitri,Rcheulishvili,Nino,Liu,Cong,et al. Strategy of developing nucleic acid-based universal monkeypox vaccine candidates[J]. Frontiers in Immunology,2022,13.
|
APA |
Papukashvili,Dimitri,Rcheulishvili,Nino,Liu,Cong,Wang,Xingyun,He,Yunjiao,&Wang,Peng George.(2022).Strategy of developing nucleic acid-based universal monkeypox vaccine candidates.Frontiers in Immunology,13.
|
MLA |
Papukashvili,Dimitri,et al."Strategy of developing nucleic acid-based universal monkeypox vaccine candidates".Frontiers in Immunology 13(2022).
|
Files in This Item: | There are no files associated with this item. |
|
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment